Evidence map›Paper›PMID 40926900›Full record

ArticleEClinicalMedicine2025

Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis.

Jiaheng Chu, Haibo Zhang, Yin Wu, Yue Huang, Tianren Zhu, Ziyi Zhou, Hui Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Tackling the epidemic of obesity and hypertension in children and young people.Current opinion in nephrology and hypertension · 2026
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiaheng ChuCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Haibo ZhangSuzhou Center for Disease Control and Prevention, Suzhou, Jiangsu 215000, China.
Yin WuCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yue HuangCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tianren ZhuCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ziyi ZhouCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hui WangCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for obesity. However, it remains inconclusive whether the combination of lifestyle modifications and GLP-1RA interventions can lead to greater weight loss and better control of cardiovascular biomarkers. We aimed to evaluate the efficacy of this combination therapy on weight loss and cardiometabolic markers in adults with overweight or obesity. Methods: We searched PubMed, Embase, and the Cochrane Library to identify randomized controlled trials published from inception until May 10, 2025 that assessed the effects of lifestyle modifications combined with GLP-1RAs in adults with overweight or obesity. The standard control group in these trials was set as lifestyle modifications combined with placebo. The efficacy outcomes were the changes of body weight, waist circumference, blood pressure, fasting blood glucose, glycated hemoglobin and lipids. Mean differences (MDs) were calculated using a random-effects model to assess the effects of lifestyle modifications combined with GLP-1RAs on weight loss and cardiometabolic markers. Risk of bias was assessed with the Cochrane risk-of-bias algorithm, with overall certainty of evidence evaluated by Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool. This study is registered with PROSPERO (CRD42024600250). Findings: A total of 33 randomized controlled trials involving 12,028 participants were included. Lifestyle modification combined with GLP-1RAs results in a significant mean weight loss of 7.13 kg compared with control groups (MD: -7.13 kg, 95% CI: -9.02, -5.24, Interpretation: Lifestyle interventions combined with GLP-1RAs may help reduce body weight and improve cardiometabolic biomarkers in adults with overweight or obesity. In light of the varying certainty of evidence across outcomes, these results should be interpreted cautiously. Treatment duration, drug type, dosage, and geographic region were key influencing factors of intervention effectiveness. Funding: Startup Fund for Young Faculty at Shanghai Jiao Tong University (Grant No. KJ3-0214-24-0011).

Indexed as

Body compositionCardiometabolic biomarkersGLP-1RAsLifestyle modificationRandomized controlled trials

Identifiers

PMID40926900
PMCPMC12414836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.